Mechanisms Underlying Lung Resistance- Related Protein (LRP)-Mediated Doxorubicin Resistance of Non-Small Cell Lung Cancer Cells

10.4077/CJP.2016.BAF426

Yu-Lun Chen；Tsung-Ying Yang；Chieh-Liang Wu；Kun-Chieh Chen；Shih-Lan Hsu；Chi-Mei Hsueh

NSCLC ； DOX resistance ； LRP ； vPARP ； TEP1

The Chinese Journal of Physiology

59卷6期（2016 / 12 / 31）

331 - 347

英文

Lung resistance-related protein (LRP) is a human major vault protein (MVP) implicated in drug resistance of cancer cells in a cell-type dependent manner. The primary goal of the study was to understand the role(s) of LRP in doxorubicin (DOX) resistance of non-small cell lung cancer (NSCLC) cells and the underlying working mechanisms. In the study, the roles of LRP in the regulation of DOX dynamics, nuclear import of minor vault proteins (vault poly (ADP-ribose) polymerase, vPARP and telomerase associated protein-1, TEP-1) and DOX-mediated cytotoxicity were examined in CH27 and H460 cells. Our results were the first to show that the CH27 cells with higher LRP expression levels were more resistant to DOX-induced cytotoxicity as shown in apoptosis experiments. LRP at the nuclear membrane could regulate DOX efflux from the nucleus to the cytosol, and also the reverse vPARP/TEP1 influx from the cytosol, to protect NSCLC cells from DOX-induced apoptosis. Cytosolic LRP could bind to DOX, vPARP and TEP1 to clear DOX away from the nucleus and promote the assembly of vaults for cell protection again. Based on the data obtained, the molecular mechanisms responsible for DOX resistance of NSCLC were delineated to demonstrate that LRP, vPARP and TEP1 were potential targets for NSCLC therapy. Inhibitors of these proteins, including small interfering LRP (siLRP), wheat-germ agglutenin (WGA), 3-aminobenzamide (3-AB) and 3,6,9-trisubstituted acridine 9-[4-(N,N-dimethylamino) phenylamino]-3,6-bis(3-pyrrolodinopropionamido) acridine (BRACO-19), break down the DOX resistance of NSCLC cells, particularly in CH27 cells, and may have therapeutic values in the control of NSCLC.

1. Adam, S.A.,Marr, R.S.,Gerace, L.(1990).Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors.J. Cell Biol.,111,807-816.
2. Andreopoulou, E.,Sparano, J.A.(2013).Chemotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer: an overview.Curr. Breast Cancer Rep.,5,42-50.
3. Berger, W.,Elbling, L.,Micksche, M.(2000).Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.Int. J. Cancer.,88,293-300.
4. Bradford, M.M.(1976).A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal. Biochem.,72,248-254.
5. Chen, S.Y.,Hu, S.S.,Dong, Q.,Cai, J.X.,Zhang, W.P.,Sun, J.Y.,Wang, T.T.,Xie, J.,He, H.R.,Xing, J.F.,Lu, J.,Dong, Y.L.(2013).Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.Asian Pac. J. Cancer Prev.,14,6135-6140.
6. Chen, Y.L.,Yang, T.Y.,Chen, K.C.,Wu, C.L.,Hsu, S.L.,Hsueh, C.M.(2016).Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.Cell. Oncol.,39,411-433.
7. Chugani, D.C.,Rome, L.H.,Kedersha, N.L.(1993).Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex.J. Cell Sci.,106(Pt 1),23-29.
8. Chung, J.H.,Ginn-Pease, M.E.,Eng, C.(2005).Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein.Cancer Res.,65,4108-4116.
9. D'Arpa, P.,Liu, L.F.(1989).Topoisomerase-targeting antitumor drugs.Biochim. Biophys. Acta.,989,163-177.
10. Dietel, M.,Arps, H.,Lage, H.,Niendorf, A.(1990).Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257.Cancer Res.,50,6100-6106.
11. Dingemans, A.M.,van Ark-Otte, J.,van der Valk, P.,Apolinario, R.M.,Scheper, R.J.,Postmus, P.E.,Giaccone, G.(1996).Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.Ann. Oncol.,7,625-630.
12. Feldherr, C.M.,Akin, D.,Cohen, R.J.(2001).Regulation of functional nuclear pore size in fibroblasts.J. Cell Sci.,114,4621-4627.
13. Gariboldi, M.B.,Ravizza, R.,Riganti, L.,Meschini, S.,Calcabrini, A.,Marra, M.,Arancia, G.,Dolfini, E.,Monti, E.(2003).Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines.Int. J. Oncol.,22,1057-1064.
14. Goto, S.,Ihara, Y.,Urata, Y.,Izumi, S.,Abe, K.,Koji, T.,Kondo, T.(2001).Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.FASEB J.,15,2702-2714.
15. Gottesman, M.M.,Fojo, T.,Bates, S.E.(2002).Multidrug resistance in cancer: role of ATP-dependent transporters.Nat. Rev. Cancer,2,48-58.
16. Huang, S.T.,Wang, C.Y.,Yang, R.C.,Chu, C.J.,Wu, H.T.,Pang, J.H.(2010).Wogonin, an active compound in Scutellaria baicalensis, induces apoptosis and reduces telomerase activity in the HL-60 leukemia cells.Phytomedicine,17,47-54.
17. Ihde, D.C.,Minna, J.D.(1991).Non-small cell lung cancer. Part II: Treatment.Curr. Probl. Cancer.,15,105-154.
18. Izquierdo, M.A.,Scheffer, G.L.,Flens, M.J.,Schroeijers, A.B.,van der Valk, P.,Scheper, R.J.(1996).Major vault protein LRP-related multidrug resistance.Eur. J. Cancer,32A,979-984.
19. Javle, M.,Curtin, N.J.(2011).The role of PARP in DNA repair and its therapeutic exploitation.Brit. J. Cancer.,105,1114-1122.
20. Kalyanaraman, B.,Joseph, J.,Kalivendi, S.,Wang, S.,Konorev, E.,Kotamraju, S.(2002).Doxorubicin-induced apoptosis: implications in cardiotoxicity.Mol. Cell Biochem.,234-235,119-124.
21. Kedersha, N.L.,Rome, L.H.(1986).Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA.J. Cell Biol.,103,699-709.
22. Kickhoefer, V.A.,Liu, Y.,Kong, L.B.,Snow, B.E.,Stewart, P.L.,Harrington, L.,Rome, L.H.(2001).The Telomerase/vault-associated protein TEP1 is required for vault RNA stability and its association with the vault particle.J. Cell Biol.,152,157-164.
23. Kickhoefer, V.A.,Siva, A.C.,Kedersha, N.L.,Inman, E.M.,Ruland, C.,Streuli, M.,Rome, L.H.(1999).The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase.J. Cell Biol.,146,917-928.
24. Kitazono, M.,Sumizawa, T.,Takebayashi, Y.,Chen, Z.S.,Furukawa, T.,Nagayama, S.,Tani, A.,Takao, S.,Aikou, T.,Akiyama, S.(1999).Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.J. Natl. Cancer Inst.,91,1647-1653.
25. Koley, D.,Bard, A.J.(2010).Triton X-100 concentration effects on membrane permeability of a single HeLa cell by scanning electrochemical microscopy (SECM).Proc. Natl. Acad. Sci. USA,107,16783-16787.
26. Kong, L.B.,Siva, A.C.,Rome, L.H.,Stewart, P.L.(1999).Structure of the vault, a ubiquitous celular component.Structure,7,371-379.
27. Lin, L.C.,Hsu, S.L.,Wu, C.L.,Liu, W.C.,Hsueh, C.M.(2011).Peroxisome proliferator-activated receptor gamma (PPARgamma) plays a critical role in the development of TGFbeta resistance of H460 cell.Cell. Signal.,23,1640-1650.
28. Lu, D.,Shi, H.C.,Wang, Z.X.,Gu, X.W.,Zeng, Y.J.(2011).Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.Brit. J. Biomed. Sci.,68,69-74.
29. Lu, J.H.,Shi, Z.F.,Xu, H.(2014).The mitochondrial cyclophilin D/p53 complexation mediates doxorubicin-induced non-apoptotic death of A549 lung cancer cells.Mol. Cell Biochem.,389,17-24.
30. Mossink, M.H.,van Zon, A.,Franzel-Luiten, E.,Schoester, M.,Kickhoefer, V.A.,Scheffer, G.L.,Scheper, R.J.,Sonneveld, P.,Wiemer, E.A.(2002).Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics.Cancer Res.,62,7298-7304.
31. Mossink, M.H.,van Zon, A.,Scheper, R.J.,Sonneveld, P.,Wiemer, E.A.(2003).Vaults: a ribonucleoprotein particle involved in drug resistance?.Oncogene,22,7458-7467.
32. Nooter, K.,Bosman, F.T.,Burger, H.,van Wingerden, K.E.,Flens, M.J.,Scheper, R.J.,Oostrum, R.G.,Boersma, A.W.,van der Gaast, A.,Stoter, G.(1996).Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.Ann. Oncol.,7,75-81.
33. Otterson, G.A.,Villalona-Calero, M.A.,Hicks, W.,Pan, X.,Ellerton, J.A.,Gettinger, S.N.,Murren, J.R.(2010).Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.Clin. Cancer Res.,16,2466-2473.
34. Pommier, Y.,Schwartz, R.E.,Kohn, K.W.,Zwelling, L.A.(1984).Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents.Biochemistry,23,3194-3201.
35. Qiang, F.,Guangguo, R.,Yongtao, H.,Dandan, D.,Hong, Y.(2013).Multidrug resistance in primary tumors and metastases in patients with esophageal squamous cell carcinoma.Pathol. Oncol. Res.,19,641-648.
36. Ranek, M.J.,Wang, X.(2009).Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.Curr. Hypertens. Rep.,11,389-395.
37. Rome, L.,Kedersha, N.,Chugani, D.(1991).Unlocking vaults: organelles in search of a function.Trends. Cell Biol.,1,47-50.
38. Rout, M.P.,Wente, S.R.(1994).Pores for thought: nuclear pore complex proteins.Trends. Cell Biol.,4,357-365.
39. Scheffer, G.L.,Wijngaard, P.L.,Flens, M.J.,Izquierdo, M.A.,Slovak, M.L.,Pinedo, H.M.,Meijer, C.J.,Clevers, H.C.,Scheper, R.J.(1995).The drug resistance-related protein LRP is the human major vault protein.Nat. Med.,1,578-582.
40. Scheper, R.J.,Broxterman, H.J.,Scheffer, G.L.,Kaaijk, P.,Dalton, W.S.,van Heijningen, T.H.,van Kalken, C.K.,Slovak, M.L.,de Vries, E.G.,van der Valk, P.(1993).Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.Cancer Res.,53,1475-1479.
41. Schuurhuis, G.J.,Broxterman, H.J.,de Lange, J.H.,Pinedo, H.M.,van Heijningen, T.H.,Kuiper, C.M.,Scheffer, G.L.,Scheper, R.J.,van Kalken, C.K.,Baak, J.P.(1991).Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.Brit. J. Cancer.,64,857-861.
42. Sibani, S.,Price, G.B.,Zannis-Hadjopoulos, M.(2005).Decreased origin usage and initiation of DNA replication in haploinsufficient HCT116 Ku80+/- cells.J. Cell Sci.,118,3247-3261.
43. Siva, A.C.,Raval-Fernandes, S.,Stephen, A.G.,LaFemina, M.J.,Scheper, R.J.,Kickhoefer, V.A.,Rome, L.H.(2001).Up-regulation of vaults may be necessary but not sufficient for multidrug resistance.Int. J. Cancer.,92,195-202.
44. Slesina, M.,Inman, E.M.,Rome, L.H.,Volknandt, W.(2005).Nuclear localization of the major vault protein in U373 cells.Cell Tissue Res.,321,97-104.
45. Sung, J.M.,Cho, H.J.,Yi, H.,Lee, C.H.,Kim, H.S.,Kim, D.K.,Abd El-Aty, A.M.,Kim, J.S.,Landowski, C.P.,Hediger, M.A.,Shin, H.C.(2008).Characterization of a stem cell population in lung cancer A549 cells.Biochem. Biophys. Res. Commun.,371,163-167.
46. Theodossiou, T.A.,Galanou, M.C.,Paleos, C.M.(2008).Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells.J. Med. Chem.,51,6067-6074.
47. Tymianski, M.,Charlton, M.P.,Carlen, P.L.,Tator, C.H.(1993).Secondary Ca2+ overload indicates early neuronal injury which precedes staining with viability indicators.Brain Res.,607,319-323.
48. van Zon, A.,Mossink, M.H.,Houtsmuller, A.B.,Schoester, M.,Scheffer, G.L.,Scheper, R.J.,Sonneveld, P.,Wiemer, E.A.(2006).Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope.Exp. Cell Res.,312,245-255.
49. Wang, X.Q.,Li, H.,Van Putten, V.,Winn, R.A.,Heasley, L.E.,Nemenoff, R.A.(2009).Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9.Mol. Biol. Cell.,20,791-800.
50. Yoshida, M.,Suzuki, T.,Komiya, T.,Hatashita, E.,Nishio, K.,Kazuhiko, N.,Fukuoka, M.(2001).Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin.Int. J. Cancer.,94,432-437.